Silver nanoparticles induce a *triclosan-like* antibacterial action mechanism in multi-drug resistant *Klebsiella pneumoniae*

Vikram Pareek[1, 2], Stéphanie Devineau[3], Sathesh K. Sivasankaran[4], Arpit Bhargava[2], Jitendra Panwar[2]*, Shabarinath Srikumar[5] and Séamus Fanning[1,6]*

[1] UCD-Centre for Food Safety, UCD School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin D04 V1W8, Ireland

[2] Department of Biological Sciences, Birla Institute of Technology & Science, Pilani 333031, India

[3] Université de Paris, BFA, UMR 8251, CNRS, F-75013 Paris, France

[4] Genome Informatics Facility, Iowa State University, 448 Bessy Hall, Ames, IA, 50011, USA

[5] Department of Food, Nutrition and Health, College of Food and Agriculture, UAE University, Al Ain, UAE

[6] Institute for Global Food Security, Queen's University Belfast, 19 Chlorine Gardens, Belfast BT9 5DL, United Kingdom

* jpanwar@pilani.bits-pilani.ac.in

* sfanning@ucd.ie

Abstract

Objectives: Infections associated with antimicrobial-resistant bacteria now represent a significant threat to human health using conventional therapy, necessitating the development of alternate and more effective antibacterial compounds. Silver nanoparticles (Ag NPs) have been proposed as potential antimicrobial agents to combat infections. A complete understanding of their antimicrobial activity is required before these molecules can be used in therapy.

Methods: Lysozyme coated Ag NPs were synthesized and characterized by TEM-EDS, XRD, UV-vis, FTIR spectroscopy, zeta potential and oxidative potential assay. Biochemical assays and deep level transcriptional analysis using RNA sequencing were used to decipher how Ag NPs exert their antibacterial action against multi-drug resistant *Klebsiella pneumoniae* MGH78578.

Results: RNAseq data revealed that Ag NPs induced a *triclosan-like* bactericidal mechanism responsible for the inhibition of the type II fatty acid biosynthesis. Additionally, released Ag^+ generated oxidative stress both extra- and intracellularly in *K. pneumoniae*. The data showed that *triclosan-like* activity and oxidative stress cumulatively underpinned the antibacterial activity of Ag NPs. This result was confirmed by the analysis of the bactericidal effect of Ag NPs against the isogenic *K. pneumoniae* MGH78578 *ΔsoxS* mutant, which exhibits a compromised oxidative stress response compared to the wild type.

Conclusion: Silver nanoparticles induce a *triclosan-like* antibacterial action mechanism in multi-drug resistant *K. pneumoniae*. This study extends our understanding of anti-*Klebsiella*

mechanisms associated with exposure to Ag NPs. This allowed us to model how bacteria might develop resistance against silver nanoparticles, should the latter be used in therapy.

Keywords: Silver nanoparticles; *Klebsiella pneumoniae*; RNA sequencing; soxS; triclosan.

Introduction

Antimicrobial resistance (AMR) is responsible for approximately 700,000 deaths annually across the globe and this number is expected to increase further if new measures are not adopted and antibacterial compounds discovered.[1] The emergence of multi-drug resistance (MDR) in various pathogenic bacterial species represents a serious public health challenge,[2,3] leading to hospital- and community-acquired infections, which are difficult to treat and control.[4,5] Since AMR is estimated to overtake cancer as the main cause of death in 50 years, innovative approaches including the development of novel antimicrobial strategies using silver nanoparticles (Ag NPs) are required.[6,7]

Klebsiella pneumoniae is one of the members of the ESKAPE pathogens (representing *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacter* spp.).[4] It is a member of Enterobacteriaceae family - Gram-negative, non-motile, and rod-shaped. This bacterium is considered an opportunistic pathogen commonly found in the intestine, mouth, and skin of humans. It is mainly associated with hospital-acquired infections (nosocomial infections) and responsible for respiratory/urinary tract infections, pneumonia, and sepsis.[1,8,9] This pathogen can also form biofilms on indwelling medical devices leading to persistent nosocomial infection.[10,11] About 25 % of nosocomial *K. pneumoniae* were found to be resistant to carbapenem-based compounds.[12,13] *K. pneumoniae* were also found to be resistant to colistin, a last-line antibiotic.[14,15] The emergence of AMR in *K. pneumoniae* against critically important classes of antibiotics represents a major threat to conventional clinical therapy.[11,16] Novel antibacterial strategies are required to overcome this challenge.[17,18]

Silver and other metals such as copper and zinc have historically been used as potential antibacterial agents.[19,20] Antibacterial activity of silver can vary depending on its chemical form.[21–23] Metallic forms continuously release small numbers of ions, which makes it a slow-acting agent, whilst the ionic form is more efficient. Although Ag^+ is reported to exhibit better antibacterial activity,[24] direct exposure to mammalian cells has toxic side effects that limit its application in therapy.[25,26] In contrast, Ag NPs provide a greater surface area, leading to a more controlled release of Ag^+.[27] Hence, this form has potential as an antibacterial compound.[28,29] Despite this advantage, little is known about the antibacterial action mechanisms of Ag NP based formulations.

We synthesized lysozyme coated Ag NPs (L-Ag NPs) and characterized their antibacterial mechanism against MDR *K. pneumonia* MGH78578 using chemical analysis, biochemical assays and deep-level RNA sequencing. Our data revealed that L-Ag NPs induced a *triclosan-like*

antibacterial effect against MDR *K. pneumoniae.* The inhibition of the type II fatty acid biosynthesis along with Ag^+ induced oxidative stress were responsible for the anti-*K. pneumoniae* effect. Our results provide molecular insights into how bacteria might deploy antibacterial strategies to counteract the toxic effects of Ag NPs. This allowed us to model how *K. pneumoniae* might develop resistance against Ag NPs.[30]

Materials and Methods

Bacteria and media

Klebsiella pneumoniae MGH78578 (ATCC®700721) is a clinical isolate chosen for its MDR phenotype[31,32] and the availability of its whole genome sequence (NC_009648.1). Bacteria were grown in Luria Bertani (LB) and modified LB (mLB) media constituted without NaCl.[33,34]

Synthesis of L-Ag NPs

L-Ag NPs were synthesized following a protocol adapted from Ashraf et al (see SI).[35] To determine the size, shape, crystallinity and surface capping, L-Ag NPs were characterized by Transmission Electron Microscopy (TEM), Energy Dispersive Spectroscopy (EDS), X-ray Diffraction (XRD), UV-vis spectroscopy, Fourier Transform Infrared spectroscopy (FTIR). The zeta potential of L-Ag NPs was measured with a Zetasizer Nano ZS (Malvern Instruments). The acellular oxidative potential of L-Ag NPs was assessed by measuring the depletion in antioxidants (uric acid, ascorbic acid, reduced glutathione) by HPLC following incubation of L-Ag NPs in a simplified synthetic respiratory tract lining fluid for 4 h at 37 °C.[36] The dissolution kinetics of L-Ag NPs in mLB was measured by inductively coupled plasma optical emission spectrometry (ICP-OES) (Avio 200, PerkinElmer). All measurements were performed in duplicate. The detailed protocols are described in the supplementry information (SI) file. Freshly prepared L-Ag NPs were used for all the experiments.

Antibacterial susceptibility determinations

The minimum inhibitory concentration (MIC) was determined using the broth microdilution assay following CLSI guidelines. Bacterial cells were exposed to L-Ag NPs (ranging from 0.5 to 64 µg (Ag) mL^{-1}) and incubated at 37 °C in the dark for 24 h. Bacterial cells exposed to L-Ag NPs were spread plated and incubated for 12 h at 37 °C to determine the minimum bactericidal concentration (MBC).

Mode of action studies-measurement of reactive oxygen species (ROS)

The generation of ROS inside the bacterial cell following exposure to L-Ag NPs was measured using a 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) assay.[37] The effect of L-Ag NPs on the bacterial cell envelope was examined by TEM. A minimum number of 50 cells were imaged in each condition. The membrane damage was analyzed using the MDA and anthrone assays. The intracellular concentration of Ag was measured by ICP-OES following exposure to MIC_{75} L-Ag NPs for 5, 30 and 60 min at 37 °C. Detailed protocols are described in SI.

RNA sequencing

A freshly grown culture of *K. pneumoniae* MGH78578 from mid-log_{10} phase (approximately 10^7 CFU mL^{-1}) was exposed to MIC_{75} L-Ag NPs for 5 and 30 min at 37 °C in mLB broth. Bacterial cells not exposed to L-Ag NPs were selected as a control for each time point. RNA was isolated using RNAeasy extraction kit (Qiagen) and treated with Turbo DNase kit (Ambion's). RNA integrity was assessed using a Bioanalyzer 2100 RNA 6000 nanochip (Agilent Technologies). RNA library sequencing was performed at the Centre for Genomic Research, University of Liverpool, UK. Ribosomal RNA was removed with a Ribo-Zero rRNA removal kit (Illumina). Libraries were prepared with NEBNext Directional RNA Library Prep Kit (BioLabs). Pooled libraries (Table S1) were loaded on cBot (Illumina) and cluster generations was performed. Single-sequencing using 150 bp read length was performed on lane of the HiSeq 4000 sequencer (Illumina). Raw sequencing data was processed as described in SI. The RNAseq data produced from the present work were deposited to the NCBI-GEO database and are available under the accession number GSE151953.

Comparative gene expression analysis with E. coli MGH1655 exposed to individual antibiotics

A comparison of our transcriptional data with the global transcriptome profiling of *E. coli* MGH1665 K12 strain exposed to 37 antibiotics was carried out. Only those genes that gave statistically significant differential expression patterns were selected from both datasets. Our gene expression dataset was compared to each of the 37 *E. coli* transcriptional profiles and genes that had similar expression patterns (both up-and down-regulation) were counted.

Results and discussion

Synthesis and characterization of L-Ag NPs

L-Ag NPs were synthesized by a co-reduction method wherein lysozyme functions both as a reducing and stabilizing agent using heat reflux action at 120 °C.[35,38] Lysozyme acts as a capping material devoid of enzymatic activity. We selected L-Ag NPs based on their bactericidal activity against MDR *K. pneumoniae* MGH78578. The synthesis of L-Ag NPs was associated with the appearance of the plasmon peak at 414 nm (Figure 1A).[39] The average diameter of L-Ag NPs measured by TEM was 5.2 ± 1.2 nm (Figures 1B-C). The X-ray diffraction pattern obtained corresponds to the face-centered cubic lattice structure of crystalline silver (JCPDS file 04-0783) (Figure 1D, S1).[40,41] The surface charge of L-Ag NPs was estimated by measuring their zeta potential in water and modified LB (mLB) medium (devoid of NaCl) at 37° C. L-Ag NPs were found to be negatively charged in both conditions with ζ = -38.2 ± 1.6 mV in water and ζ = -24.2 ± 0.9 mV in mLB medium. The 1,632 cm^{-1} peak in the FTIR spectrum corresponds to the amide I vibration characteristic of the protein backbone, confirming the presence of lysozyme associated with Ag NPs (Figure 1E).[42]

L-Ag NPs inhibit the proliferation of *K. pneumoniae* MGH78578

In media with high salt content like chloride and phosphate, Ag NPs may aggregate and free Ag^+ can precipitate, potentially reducing their bactericidal activity.[34,43–45] Hence, the bactericidal effect of L-Ag NPs against *K. pneumoniae* MGH78578 was assessed in mLB medium (LB medium devoid of NaCl).[46,47] No significant difference between the growth of *K. pneumoniae* in mLB and LB media was observed (Figure 2A) confirming mLB had no phenotypic effect. Approximately 3×10^7 CFU mL^{-1} log_{10} phase bacterial cells were exposed to L-Ag NPs. The MIC of L-Ag NPs was 21 µg (Ag) mL^{-1} (Figure 2B). To determine the bactericidal efficiency of L-Ag NPs, *K. pneumoniae* MGH78578 exposed to L-Ag NPs were spread plated and incubated for 12 h at 37 °C. The MBC of L-Ag NPs was 45 µg (Ag) mL^{-1} (Figure S2). These results show that L-Ag NPs inhibit the proliferation of *K. pneumoniae* MGH78578 at low concentrations.

L-Ag NPs generate ROS and limited membrane damage in *K. pneumoniae* MGH78578

Reactive oxygen species (ROS) could be generated outside the bacterial cells by L-Ag NPs and released Ag^+.[48] Limited dissolution of L-Ag NPs was observed in mLB media for 8 h at 37°C (Figure 2C). Extracellular ROS production was evaluated by measuring the oxidative potential of L-Ag NPs in a simplified synthetic respiratory tract lining fluid. The depletion of antioxidants (uric acid, acetic acid, and reduced glutathione GSH) was also noted when measured by HPLC after 4 h incubation at 37 °C (Figure 3A).[49] We observed a dose-dependent depletion in ascorbic acid and GSH (up to 100%), showing that, at low NP concentration, L-Ag NPs can generate ROS extracellularly.

Then, we measured the concentration of silver that enter *K. pneumoniae* MGH78578 by ICP-OES following treatment with L-Ag NPs for 5, 30, and 60 min. The uptake of silver, either in the form of L-Ag NPs or Ag^+, was proportional to the time duration of treatment (Figure S3). To determine whether ROS were also produced inside the bacterial cells following exposure to L-Ag NPs, we used the DCFH-DA assay.[50] A dose-dependent increase in the intracellular ROS was observed, a reflection of the oxidative stress external to the bacterial cell (Figure 3B).

The severe oxidative stress induced by L-Ag NPs could lead to many downstream phenotypes in bacteria including compromised membrane integrity.[23,27,28,51] TEM analysis of *K. pneumoniae* did not show any change in the membrane integrity of the exposed bacterial cells (Figures 3C-D). To verify this observation, we explored the degree of bacterial membrane damage in the whole population using an MDA assay. A limited though significant concentration-dependent increase in the level of lipid peroxidation was observed (Figure 3E). Additionally, a concentration-dependent increase of carbohydrate release was observed following L-Ag NP exposure (Figure 3F). Overall, our results show that L-Ag NPs induced limited bacterial membrane damage, a phenotype that was not observed by TEM.

Transcriptomic profiling of L-Ag NPs exposed *K. pneumoniae* MGH78578 using RNA-seq

We used RNA-seq to understand how *K. pneumoniae* MGH78578 responded to L-Ag NP exposure following a previously standardized protocol investigating the transcriptome of *K. pneumoniae* MGH78578 exposed to sub-inhibitory concentrations of a chemosensitizer.[31] Here, we exposed *K. pneumoniae* MGH78578 to a sub-inhibitory concentration of L-Ag NPs at MIC_{75} (15.8 µg (Ag) mL^{-1}) for a period of 5- and 30-min. The 5 min time point was used to identify the transcriptional signals associated with early exposure, whilst the 30 min time point demonstrated the adaptive responses of L-Ag NP exposed *K. pneumoniae* (replication time is 20 min). Approximately 336 million reads were obtained across all 8 libraries with an average of 42 million reads *per* library (Table S1) sufficient for downstream transcriptomic analysis.[31,52] The *VOOM* function in the *limma* package[53] was used to identify differentially regulated genes. We obtained statistically significant data ($p \leq 0.05$) for a total of 3,760 and 3,945 genes following 5 min and 30 min exposure respectively (Figure 4A) (Dataset WS1). Statistically significant genes with a $\log_2$ fold change expression of ≥ 1.0 and ≤ -1.0 (exposed *versus* unexposed cells) were considered to be up- and down-regulated respectively.[31,54] For the post-5 min exposure, 1,008 genes were found to be upregulated and 1,063 genes were downregulated. At 30 min post exposure, 1,205 genes were found to be upregulated and 1,246 genes were downregulated (Figure 4B). Among all the upregulated genes at the 5- and 30-min, 705 genes were found to be commonly upregulated, whereas 303 and 500 genes were uniquely upregulated at 5 min and 30 min respectively. For downregulated genes, 810 genes were found to be commonly downregulated at both time points, whereas 253 and 436 genes were specifically downregulated at 5 min and 30 min (Figure 4C).

We selected representative genes related to the bacterial defence system (*soxS*), transcriptional regulator (*ramA*), outer membrane porin proteins (*ompC*) and virulence (*rfaH*) to validate our transcriptomic data using qRT-PCR. Gene expression analysis reflected a similar pattern of results when compared to RNA-seq data (Figure S4).

Bacterial oxidative stress response following exposure to L-Ag NP

Our RNA-seq data shows that the oxidative stress response induced by ROS generation is choreographed by both *soxS* and *oxyR,* two major transcriptional factors that respond to oxidative stress in Enterobacteriaceae.[55] The OxyR system functions as a global regulator of peroxide stress whilst the SoxRS system is involved in the control of superoxide stress.[55,56] Increased intracellular ROS levels induce the oxidation of OxyR protein, which in turn activates detoxifying processes including heme biosynthesis, thiol-disulfide isomerization, among others.[57] In the case of the SoxRS regulon, oxidative stress causes the oxidization of the SoxR protein, which activates the *soxS* transcriptional regulator, thereby triggering a bacterial defense mechanism involving various

efflux pumps and redox counter measures.[55] In L-Ag NP exposed *K. pneumoniae* MGH78578, *soxS* was highly upregulated (300- and 88-fold in 5 and 30 min) and in contrast *oxyR* was moderately upregulated (approximately 5-fold in both time points). This suggested that the oxidative stress regulon was active throughout the 30 min of L-Ag NP exposure time, particularly for the *soxS* regulon.

To confirm this, we compared our RNA-seq dataset to the *K. pneumoniae* MGH78578 oxidative *soxS* regulon generated earlier.[58] We found that of the 254 genes belonging to the oxidative *soxS* regulon, 129 (51%) had similar expression patterns in both datasets, confirming that the *soxS* regulon is activated in L-Ag NP exposed *K. pneumoniae* (Dataset WS2). A typical example of *soxS* induction can be visualized in the expression of *fpr* [ferredoxin-NADP$^+$ reductase], which was induced at 22- and 9-fold at 5 and 30 min. In response to *soxS* activation, a redox neutralization process is triggered related to the overexpression of *fpr* by 4.5-fold at 5 min, that then reduced to 3.2-fold at 30 min post-treatment.[59]

Activation of efflux pumps following exposure to L-Ag NP

Bacteria activate various efflux pumps to expel the toxic Ag^+.[60,61] Classic efflux pump-encoding genes such as *acrAB-tolC* [62,63] and *marRAB* were found to be highly upregulated following treatment with L-Ag NPs, a feature that was sustained throughout the testing period of 30 min, possibly driven by the positive regulation *via* SoxS.[55,58] Another efflux pump encoded by the *silCFBA* operon conferring a silver resistance phenotype was also upregulated.[61,64] Transcription of the *silCFBA* operon and *silP* are controlled by the *silRS*, which encodes a two-component system wherein SilR acts as a response regulator and SilS acts as a histidine kinase.[65,66] SilP is a P-type ATPase efflux pump, which facilitates the passage of Ag^+ from cytoplasm to the periplasm. SilF acts as a chaperone and transfers Ag^+ from periplasm to the SilCBA complex, a three-protein dependent cation/proton antiporter system. Another protein from silver resistance system is SilE, present downstream to the *silRS* (Figure 5).[65,66] Upregulation of *silC/B/E/R/S/P* and KPN_pKPN3p05946 genes were noted in our RNA-seq data showing the activation of efflux pumps, encoding a possible silver resistance in response to L-Ag NP exposure.

The type II fatty acid biosynthesis genes were down-regulated in L-Ag NP exposed *K. pneumoniae* MGH78578

Since *K. pneumoniae* MGH78578 expressed an MDR phenotype,[13] L-Ag NP exposure dependent activation of *acrAB-tolC, marRAB,* and *sil* genes should, in principle, confer silver resistance in *K. pneumoniae*. Additionally, the strong oxidative stress response should enable the bacterium to counter the oxidative stress induced by L-Ag NPs. Both of these mechanisms should render *K. pneumoniae* MGH78578 resistant against silver. However, *K. pneumoniae* MGH78578 was found

to be susceptible to L-Ag NPs. We hypothesized that the bactericidal activity of L-Ag NPs could be due to a hitherto unknown mechanism, rather than the most commonly reported oxidative stress based bactericidal activity.[27] To investigate, we compared our RNA-seq data to the transcriptional response of *E. coli* exposed to 37 antimicrobial compounds.[67] This global transcriptional profile of *E. coli* exposed to 37 antibiotics generated a list of 447 genes whose signature expression pattern characterized the mechanism of action associated with each antibiotic, leading the authors to hypothesize that the antibacterial action mechanism of any unknown/uncharacterized compounds can be deduced by comparing the transcriptional profile of a compound of interest with that of these 447 *E. coli* MG1665 K12 genes. We compared our exposed *K. pneumoniae* MGH78578 transcriptional data set with each individual dataset obtained from *E. coli* global transcriptional profile. Our comparative analysis showed that the highest number of similarly expressed gene pairs were obtained from the triclosan exposure dataset, suggesting that exposure to L-Ag NPs induced a *triclosan-like* exposure response in *K. pneumoniae* MGH78578. Some 76% of the gene pairs (73/96) at 5 min L-Ag NP exposure (Dataset WS3 and WS4) and 74% (87/117) at 30 min exposure (Dataset WS5 and WS6) had similar expression patterns compared with the *E. coli* triclosan dataset.

Triclosan is a broad-spectrum antimicrobial compound that acts by inhibiting FabI (a NADH-dependent enoylacyl carrier), a protein belonging to the type II fatty acid biosynthesis, part of a well-conserved pathway that is essential for bacterial survival. Inhibition of fatty acid biosynthesis compromises the bacterial cell membrane. During exposure to L-Ag NPs, some *K. pneumoniae* MGH78578 genes associated with type II fatty acid biosynthesis including *fabA/H/D/G/F/B* were significantly downregulated particularly during the adaptive response at 30 min. The downregulation of the different *fab* genes signals a compromised type II fatty acid biosynthesis underpinning the *triclosan-like* L-Ag NP bactericidal activity. Importantly, *fadL* and *fadD* were downregulated. FadL is a porin that transports extracellular fatty acids across the outer membrane to the inner membrane where they are activated by acyl CoA synthetase FadD. Downregulation of both *fadL* and *fadD* shows that extracellular fatty acids are not transported leading to subsequent suppression of type II fatty acid biosynthesis pathway. We, however, did not observe any differential expression in the *fabI* gene, possibly because the triclosan affects FabI post-translationally.

Recently, the TraDIS-Xpress approach involving a transposon mutant library and massively parallel sequencing of transposon chromosome junctions was used to identify *E. coli* genes that respond to triclosan exposure.[68] In comparison with these data, we identified genes that were both enriched in the *E. coli* TraDIS-Xpress dataset and that were found to be differentially expressed in our *K. pneumoniae* MGH78578 dataset. Common genes like *purL, purH, waeL, wzx* were downregulated at either one or both time points while *metB* was upregulated. Similarly, *K. pneumoniae* MGH78578 genes like *trkA, pcnB, infB,* and *ubiB/F* were downregulated at least in one or both time points,

while *lonH* was upregulated (Dataset WS1). TraDIS-Xpress selected *rbs* in their triclosan exposure screen. In *E. coli,* RbsABC forms the ABC-type high-affinity D-ribose transporter, while RbsD/K phosphorylates D-ribose to D-ribose 5-phosphate.[69] Though we did not observe a statistically significant differential expression for *rbsB,* down-regulation was observed for *rbsD* and *rbsC,* showing similarly compromised D-ribose uptake. These common observations across different datasets gave confidence to our earlier observation that L-Ag NP exposure elicits a *triclosan-like* bactericidal effect in *K. pneumoniae* inhibiting type II fatty acid biosynthesis.

The L-Ag NP based antibacterial action is cumulative of oxidative stress and fatty acid biosynthesis inhibition

We investigated whether the L-Ag NP based antibacterial effect was primarily due to type II fatty acid biosynthesis inhibition or as a cumulative effect of both oxidative stress and fatty acid biosynthesis inhibition. We exposed the isogenic *K. pneumoniae MGH78578 ΔsoxS* mutant, which has a compromised oxidative stress response mechanism,[58] to L-Ag NPs. The MIC of L-Ag NPs reduced to 15 µg mL^{-1} from 21 µg mL^{-1} showing that oxidative stress did contribute to a significant antibacterial effect. The antibacterial effect of L-Ag NPs is, therefore, a cumulative effect of both type II fatty acid biosynthesis inhibition and oxidative stress responses.

Concluding observations

L-Ag NPs were very efficient in killing MDR *K. pneumoniae* MGH78578, triggering oxidative stress and a *triclosan-like* mechanism to exert their anti-*Klebsiella* effect. With toxicity studies in appropriate cell models, L-Ag NPs may be a future candidate as a novel antimicrobial agent. We hypothesized that our RNA-seq data could provide clues as to how *K. pneumoniae* might develop resistance against L-Ag NPs. Genes including *rbsD/C, trkA, pcnB* and *infB* were downregulated during the adaptive response at 30 min. Transposon insertional mutants in *E. coli* genes *trkA, pcnB* and *infB* exhibit better survival in the presence of triclosan.[68] Further, transposon insertion in *rbsB,* inhibiting the periplasmic ribose-binding domain of the RbsABC ribose importer, gave a selective survival advantage in the presence of triclosan. We hypothesize that by downregulating these genes during the adaptive response, *K. pneumoniae* MGH78578 could elicit strategies to combat the effects of exposure whilst resistance against L-Ag NPs. Exposure to sub-inhibitory concentrations of antimicrobial compounds is one of the main drivers in the evolution of AMR. By continuous exposure to sub-inhibitory concentrations of silver and the subsequent downregulation of these genes, *K. pneumoniae* might offer a transient resistance to L-Ag NPs. This hysteresis effect might be the prelude to developing a fully expressed antimicrobial resistance mechanism against silver.

Acknowledgments

Authors are thankful to BITS Pilani, University College Dublin, and Université de Paris for providing lab facilities. VP acknowledges CSIR-SRF [09/719(0090)/2018-EMR-I] and EMBO Short Term Fellowship (ESTF 7654) for the financial support. We acknowledge Justine Renault, Linh-Chi Bui, and the Bioprofiler Facility (BFA) for the HPLC analysis. This project was supported, in part, by the Ulysses PHC Scheme.

Author Contributions

SD, SS, SF, JP designed the study. VP, AB, SD characterized the silver NPs. VP and SS carried out the RNA-seq experiments. SKS generated the bioinformatics based gene expression dataset. SS, SD, VP, SF carried out the detailed RNA-seq dataset analysis that led to the triclosan observation. All authors read and approved the manuscript.

ORCID

Vikram Pareek 0000-0003-3980-1238
Stéphanie Devineau 0000-0002-1133-5223
Sathesh K. Sivasankaran 0000-0003-3037-6001
Arpit Bhargava 0000-0001-6450-6551
Jitendra Panwar 0000-0002-0750-9745
Shabarinath Srikumar 0000-0003-3775-2831
Séamus Fanning 0000-0002-1922-8836

Competing Interest Statement

The authors declare no competing interests.

References

1. Organization WH. No time to wait: securing the future from drug-resistant infections. Report to the Secretary-General of the United Nations. *World Heal Organ Geneva* 2019.
2. Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. *J Infect Dis* 2017; **215**: S28–36.
3. Cassini A, Högberg LD, Plachouras D, *et al.* Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019; **19**: 56–66.
4. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther* 2013; **11**: 297–308.
5. Klemm EJ, Wong VK, Dougan G. Emergence of dominant multidrug-resistant bacterial clades: Lessons from history and whole-genome sequencing. *Proc Natl Acad Sci* 2018; **115**: 12872–7.
6. Gupta A, Mumtaz S, Li CH, Hussain I, Rotello VM. Combatting antibiotic-resistant bacteria using nanomaterials. *Chem Soc Rev* 2019; **48**: 415–27.
7. Huh AJ, Kwon YJ. 'Nanoantibiotics': A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. *J Control Release* 2011; **156**: 128–45.
8. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 1998; **11**: 589–603.

9. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. *Ann Clin Microbiol Antimicrob* 2012; **11**: 32.
10. Jagnow J, Clegg S. Klebsiella pneumoniae MrkD-mediated biofilm formation on extracellular matrix-and collagen-coated surfaces. *Microbiology* 2003; **149**: 2397–405.
11. Li B, Zhao Y, Liu C, Chen Z, Zhou D. Molecular pathogenesis of Klebsiella pneumoniae. *Future Microbiol* 2014; **9**: 1071–81.
12. Han JH, Goldstein EJC, Wise J, Bilker WB, Tolomeo P, Lautenbach E. Epidemiology of carbapenem-resistant Klebsiella pneumoniae in a network of long-term acute care hospitals. *Clin Infect Dis* 2016; **64**: 839–44.
13. Anes J, Hurley D, Martins M, Fanning S. Exploring the genome and phenotype of multi-drug resistant Klebsiella Pneumoniae Of clinical origin. *Front Microbiol* 2017; **8**.
14. Antoniadou A, Kontopidou F, Poulakou G, *et al.* Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. *J Antimicrob Chemother* 2007; **59**: 786–90.
15. Neuner EA, Yeh J-Y, Hall GS, *et al.* Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. *Diagn Microbiol Infect Dis* 2011; **69**: 357–62.
16. Hu Y, Anes J, Devineau S, Fanning S. Klebsiella pneumoniae: Prevalence, Reservoirs, Antimicrobial Resistance, Pathogenicity, and Infection: A Hitherto Unrecognized Zoonotic Bacterium. *Foodborne Pathog Dis* 2020.
17. Adamo R, Margarit I. Fighting Antibiotic-Resistant Klebsiella pneumoniae with “Sweet” Immune Targets. *MBio* 2018; **9**: e00874-18.
18. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front Microbiol* 2019; **10**.
19. Alexander JW. History of the medical use of silver. *Surg Infect (Larchmt)* 2009; **10**: 289–92.
20. Rai MK, Deshmukh SD, Ingle AP, Gade AK. Silver nanoparticles: The powerful nanoweapon against multidrug-resistant bacteria. *J Appl Microbiol* 2012; **112**: 841–52.
21. Mijnendonckx K, Leys N, Mahillon J, Silver S, Van Houdt R. Antimicrobial silver: uses, toxicity and potential for resistance. *Biometals* 2013; **26**: 609–21.
22. Li R, Chen J, Cesario TC, Wang X, Yuan JS, Rentzepis PM. Synergistic reaction of silver nitrate, silver nanoparticles, and methylene blue against bacteria. *Proc Natl Acad Sci U S A* 2016; **113**: 13612–7.
23. Zheng K, Setyawati MI, Leong DT, Xie J. Antimicrobial silver nanomaterials. *Coord Chem Rev* 2018; **357**: 1–17.
24. Randall CP, Oyama LB, Bostock JM, Chopra I, O’Neill AJ. The silver cation (Ag+): antistaphylococcal activity, mode of action and resistance studies. *J Antimicrob Chemother* 2012; **68**: 131–8.
25. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. *Angew Chemie Int Ed* 2013; **52**: 1636–53.
26. Vimbela G V., Ngo SM, Fraze C, Yang L, Stout DA. Antibacterial properties and toxicity from metallic nanomaterials. *Int J Nanomedicine* 2017; **12**: 3941–65.
27. Durán N, Durán M, de Jesus MB, Seabra AB, Fávaro WJ, Nakazato G. Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity. *Nanomedicine Nanotechnology, Biol Med* 2016; **12**: 789–99.
28. Kang J, Dietz MJ, Hughes K, Xing M, Li B. Silver nanoparticles present high intracellular and extracellular killing against Staphylococcus aureus. *J Antimicrob Chemother* 2019; **74**: 1578–85.
29. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet J baptiste. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. *J Antimicrob Chemother* 2008; **61**: 869–76.
30. Chopra I. The increasing use of silver-based products as antimicrobial agents: A useful development or a cause for concern? *J Antimicrob Chemother* 2007; **59**: 587–90.
31. Anes J, Sivasankaran SK, Muthappa DM, Fanning S, Srikumar S. Exposure to sub-inhibitory concentrations of the chemosensitizer 1-(1-naphthylmethyl)-piperazine creates membrane destabilization in multi-drug resistant Klebsiella pneumoniae. *Front Microbiol* 2019; **10**: 1–14.
32. Ogawa W, Li D-W, Yu P, *et al.* Multidrug resistance in Klebsiella pneumoniae MGH78578 and

cloning of genes responsible for the resistance. *Biol Pharm Bull* 2005; **28**: 1505–8.
33. Bhargava A, Pareek V, Roy Choudhury S, Panwar J, Karmakar S. Superior Bactericidal Efficacy of Fucose-Functionalized Silver Nanoparticles against *Pseudomonas aeruginosa* PAO1 and Prevention of Its Colonization on Urinary Catheters. *ACS Appl Mater Interfaces* 2018; **10**: 29325–37.
34. Chambers BA, Afrooz ARMN, Bae S, *et al.* Effects of chloride and ionic strength on physical morphology, dissolution, and bacterial toxicity of silver nanoparticles. *Environ Sci Technol* 2013; **48**: 761–9.
35. Ashraf S, Chatha MA, Ejaz W, Janjua HA, Hussain I. Lysozyme-coated silver nanoparticles for differentiating bacterial strains on the basis of antibacterial activity. *Nanoscale Res Lett* 2014; **9**: 1–10.
36. Boland S, Baeza-squiban A. *Acellular antioxidant depletion assay. SOP WP3 nanOxiMet*. 2015.
37. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. *Free Radic Biol Med* 1999; **27**: 612–6.
38. Eby DM, Schaeublin NM, Farrington KE, Hussain SM, Johnson GR. Lysozyme catalyzes the formation of antimicrobial silver nanoparticles. *ACS Nano* 2009; **3**: 984–94.
39. Singh DK, Kumar J, Sharma VK, *et al.* Mycosynthesis of bactericidal silver and polymorphic gold nanoparticles: physicochemical variation effects and mechanism. *Nanomedicine* 2018; **13**: 191–207.
40. Jain N, Bhargava A, Majumdar S, Tarafdar JC, Panwar J. Extracellular biosynthesis and characterization of silver nanoparticles using Aspergillus flavus NJP08: a mechanism perspective. *Nanoscale* 2011; **3**: 635–41.
41. Pareek V, Bhargava A, Panwar J. Biomimetic approach for multifarious synthesis of nanoparticles using metal tolerant fungi: A mechanistic perspective. *Mater Sci Eng B* 2020; **262**: 114771.
42. Baker MJ, Trevisan J, Bassan P, *et al.* Using Fourier transform IR spectroscopy to analyze biological materials. *Nat Protoc* 2014; **9**: 1771.
43. Lok C-N, Ho C-M, Chen R, *et al.* Silver nanoparticles: partial oxidation and antibacterial activities. *JBIC J Biol Inorg Chem* 2007; **12**: 527–34.
44. McQuillan JS, Groenaga Infante H, Stokes E, Shaw AM. Silver nanoparticle enhanced silver ion stress response in Escherichia coli K12. *Nanotoxicology* 2012; **6**: 857–66.
45. Pareek V, Gupta R, Panwar J. Do physico-chemical properties of silver nanoparticles decide their interaction with biological media and bactericidal action? A review. *Mater Sci Eng C* 2018; **90**: 739–49.
46. Pelletier DA, Suresh AK, Holton GA, *et al.* Effects of engineered cerium oxide nanoparticles on bacterial growth and viability. *Appl Environ Microbiol* 2010; **76**: 7981–9.
47. Chatterjee S, Bandyopadhyay A, Sarkar K. Effect of iron oxide and gold nanoparticles on bacterial growth leading towards biological application. *J Nanobiotechnology* 2011; **9**: 34.
48. Le Ouay B, Stellacci F. Antibacterial activity of silver nanoparticles: A surface science insight. *Nano Today* 2015; **10**: 339–54.
49. Crobeddu B, Aragao-Santiago L, Bui LC, Boland S, Baeza Squiban A. Oxidative potential of particulate matter 2.5 as predictive indicator of cellular stress. *Environ Pollut* 2017; **230**: 125–33.
50. Aranda A, Sequedo L, Tolosa L, *et al.* Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells. *Toxicol Vitr* 2013; **27**: 954–63.
51. Zou L, Wang J, Gao Y, *et al.* Synergistic antibacterial activity of silver with antibiotics correlating with the upregulation of the ROS production. *Sci Rep* 2018; **8**: 1–11.
52. Haas BJ, Chin M, Nusbaum C, Birren BW, Livny J. How deep is deep enough for RNA-Seq profiling of bacterial transcriptomes? *BMC Genomics* 2012; **13**: 734.
53. Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015; **43**: e47–e47.
54. Dash S, Sarashetti PM, Rajashekar B, Chowdhury R, Mukherjee S. TGF-β2-induced EMT is dampened by inhibition of autophagy and TNF-α treatment. *Oncotarget* 2018; **9**: 6433.
55. Seo SW, Kim D, Szubin R, Palsson BO. Genome-wide Reconstruction of OxyR and SoxRS

Transcriptional Regulatory Networks under Oxidative Stress in Escherichia coli K-12 MG1655. *Cell Rep* 2015; **12**: 1289–99.
56. Zheng M, Åslund F, Storz G. Activation of the OxyR transcription factor by reversible disulfide bond formation. *Science (80-)* 1998; **279**: 1718–22.
57. Dubbs JM, Mongkolsuk S. Peroxide-sensing transcriptional regulators in bacteria. *J Bacteriol* 2012; **194**: 5495–503.
58. Anes J, Dever K, Eshwar A, *et al.* Analysis of the oxidative stress regulon identifies soxS as a genetic target for resistance reversal in multi-drug resistant Klebsiella pneumoniae. *bioRxiv* 2020.
59. Krapp AR, Rodriguez RE, Poli HO, Paladini DH, Palatnik JF, Carrillo N. The flavoenzyme ferredoxin (flavodoxin)-NADP (H) reductase modulates NADP (H) homeostasis during the soxRS response of Escherichia coli. *J Bacteriol* 2002; **184**: 1474–80.
60. Gurbanov R, S. Ozek N, Tunçer S, Severcan F, Gozen AG. Aspects of silver tolerance in bacteria: infrared spectral changes and epigenetic clues. *J Biophotonics* 2018; **11**: e201700252.
61. Randall CP, Gupta A, Jackson N, Busse D, O'Neill AJ. Silver resistance in Gram-negative bacteria: A dissection of endogenous and exogenous mechanisms. *J Antimicrob Chemother* 2014; **70**: 1037–46.
62. Hirakata Y, Kondo A, Hoshino K, *et al.* Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. *Int J Antimicrob Agents* 2009; **34**: 343–6.
63. Baugh S, Phillips CR, Ekanayaka AS, Piddock LJ V, Webber MA. Inhibition of multidrug efflux as a strategy to prevent biofilm formation. *J Antimicrob Chemother* 2013; **69**: 673–81.
64. Elkrewi E, Randall CP, Ooi N, Cottell JL, O'Neill AJ. Cryptic silver resistance is prevalent and readily activated in certain Gram-negative pathogens. *J Antimicrob Chemother* 2017; **72**: 3043–6.
65. Starodub ME, Trevors JT. Silver resistance in Escherichia coli R1. *J Med Microbiol* 1989; **29**: 101–10.
66. Massani MB, Klumpp J, Widmer M, *et al.* Chromosomal Sil system contributes to silver resistance in E. coli ATCC 8739. *BioMetals* 2018; **31**: 1101–14.
67. O'Rourke A, Beyhan S, Choi Y, *et al.* Mechanism-of-action classification of antibiotics by global transcriptome profiling. *Antimicrob Agents Chemother* 2020; **64**.
68. Yasir M, Turner AK, Bastkowski S, *et al.* TraDIS-Xpress: a high-resolution whole-genome assay identifies novel mechanisms of triclosan action and resistance. *Genome Res* 2020; **30**: 239–49.
69. Shimada T, Kori A, Ishihama A. Involvement of the ribose operon repressor RbsR in regulation of purine nucleotide synthesis in Escherichia coli. *FEMS Microbiol Lett* 2013; **344**: 159–65.

Figures and Tables



Figure 1. Characterization of L-Ag NPs. (A) UV-visible spectrum (inset shows a picture of the L-Ag NP suspension after synthesis). (B) TEM image. (C) Distribution of L-Ag NP diameter determined from TEM analysis. (D) XRD diffraction spectrum. (E) FTIR spectrum.



Figure 2. (A) Bacterial growth curve analysis of *K. pneumoniae* MGH78578 in LB and mLB media. (B) Determination of *K. pneumoniae* L-Ag NP MIC in mLB medium. (C) Dissolution kinetics of L-Ag NPs in mLB medium at 37°C.



Figure 3. (A) Acellular oxidative potential of L-Ag NPs measured by the depletion of antioxidants, uric acid (UA), ascorbic acid (AA), and reduced glutathione (GSH), in simplified synthetic lung lining fluid at 37°C. (B) Analysis of the intracellular ROS generation in *K. pneumoniae* MGH78578 following exposure to L-Ag NPs by the DCFH-DA assay. (C,D) Representative TEM images of untreated *K. pneumoniae* (control) (C) and *K. pneumoniae* exposed to MIC75 of L-Ag NPs (D). (E,F) Membrane damage analysis of *K. pneumoniae* following exposure to L-Ag NPs. Analysis by MDA assay (E) and anthrone assay (F).



Figure 4. Overview of the RNAseq analysis of *K. pneumoniae* MGH78578 following treatment with MIC_{75} L-Ag NPs. (A) Statistically significant and insignificant genes recorded at 5 and 30 min post-treatment. (B) Statistically significant upregulated, downregulated and neutral genes identified at 5 and 30 min post-treatment. (C) Comparison of the upregulated, downregulated, and neutral genes identified at 5 and 30 min post-treatment.



Figure 5. A model depicting the bactericidal action of L-Ag NPs on *K. pneumoniae* MGH78578. L-Ag NPs and silver ions (Ag^+) enter the bacterial cell *via* outer membrane porins. Increasing cytoplasmic Ag^+ concentration elicits the production of reactive oxygen species (ROS) including superoxide radicals, which then activate the *soxS*-mediated oxidative stress response. The SilE efflux system functions to eliminate Ag^+ from the cytoplasm. RNA-seq data identified 7 genes (denoted by the green arrowheads) associated with type II fatty acid biosynthesis that are down-regulated leading to reduced phospholipid biosynthesis. This reduction in phospholipid turnover will affect the membrane stability leading to cell lysis underpinning the bactericidal activity. Grey arrows represent genes that are activated. White arrows represent genes that are either not identified in the *K. pneumoniae* MGH78578 genome or not differentially regulated when the bacteria are exposed to L-Ag NPs.